Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SpringWorks Therapeutics, Inc. - common stock (NQ:SWTX)

46.99 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SpringWorks Therapeutics, Inc. - common stock

< Previous 1 2 3 4 5 6 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
SpringWorks Catapults 24% On A 'Watershed Moment' In Cancer Treatment ↗
The company gained FDA approval for Ogsiveo, a treatment for desmoid tumors. 
Via Investor's Business Daily
News headline image
PDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults... 
Via Benzinga
News headline image
Analyst Ratings for SpringWorks Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Ratings for SpringWorks Therapeutics ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for SpringWorks Therapeutics ↗
 
Via Benzinga
News headline image
FDA Approves SpringWorks Therapeutics' Lead Therapy As First For Subtype Of Soft Tissue Sarcomas ↗
The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who  
Via Benzinga
News headline image
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
HC Wainwright & Co. Maintains Buy Rating for SpringWorks Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today? ↗
SpringWorks Therapeutics Inc (NASDAQ: SWTX) released topline results from its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with... 
Via Benzinga
News headline image
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Analyst Expectations for SpringWorks Therapeutics's Future ↗
 
Via Benzinga
News headline image
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update ↗
In March, the FDA issued SpringWorks Therapeutics Inc (NASDAQ: SWTX) with a Form 483 letter due to a failure to ensure that the analysis of an exploratory endpoint in the Phase 3 DeFi trial, which... 
Via Benzinga
News headline image
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
FDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023 
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.